Trinity Biotech (TRIB) received notice from the Nasdaq Stock Market LLC that the company is not in compliance with Nasdaq Listing Rule ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next ...

Trinity Biotech (TRIB) announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive finan ...

The stock has a market cap of $12.48 million, a PE ratio of -0.31 and a beta of 1.20. Trinity Biotech has a twelve month low of $0.63 and a twelve month high of $3.55. An institutional investor ...

DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...

Trinity Biotech PLC (NASDAQ:TRIB), a leading diagnostic substances company with a market capitalization of $13.12 million, has successfully amended and restated its credit and guaranty agreement ...

Trinity Biotech plc, a biotechnology company specializing in human diagnostics and diabetes management, announced it has secured an additional $4 million in debt financing from Perceptive Advisors.

Trinity Biotech PLC (NASDAQ:TRIB), a leading diagnostic substances company with a market capitalization of $13.12 million, has successfully amended and restated its credit and guaranty agreement, as ...